{"id":116755,"date":"2026-09-03T13:34:10","date_gmt":"2026-09-03T13:34:10","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/116755\/"},"modified":"2026-09-03T13:34:10","modified_gmt":"2026-09-03T13:34:10","slug":"gsk-inks-another-asia-alliance-betting-up-to-1-3b-for-hutchmeds-cancer-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/116755\/","title":{"rendered":"GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED\u2019s cancer therapy"},"content":{"rendered":"

GSK continues to look eastward for novel assets, this time partnering with Hong Kong-based HUTCHMED to develop an investigational cancer therapy.<\/p>\n

The deal includes a $110 million upfront payment from the pharma, which could also be on the hook for up to $1.185 billion in development, regulatory and commercial milestones, according to a Thursday announcement<\/a>. HUTCHMED, which also has offices in mainland China and the U.S., will additionally be eligible for royalties on net sales.<\/p>\n

The star of Thursday\u2019s deal is HMPL-A830, an investigational asset that combines an EGFR-targeting monoclonal antibody with a small-molecule payload designed to inhibit the KRAS protein. This construct, which HUTCHMED calls an antibody-targeted therapy conjugate (ATTC), allows for \u201csynergistic anti-tumor activity,\u201d according to the news release.<\/p>\n

\u201cThe dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care,\u201d Hesham Abdullah, global head of Oncology R&D at GSK, said in a prepared statement.<\/p>\n

The partners will focus initial development efforts on colorectal, pancreatic and lung cancers, with HUTCHMED taking responsibility over Phase 1 studies. Thereafter, GSK will take over all subsequent clinical development. GSK will have worldwide rights over the development and commercialization of HMPL-A830, except for in mainland China, Hong Kong, Macau and Taiwan, where HUTCHMED retains full control over the asset.<\/p>\n

The HUTCHMED deal adds to GSK\u2019s growing roster of Asian partners. In January, the pharma paid $20 million upfront<\/a> and promised up to $265 million in milestones to tie up with South Korea\u2019s Alteogen, gaining access to technology that would allow GSK to create an under-the-skin formulation of its cancer drug Jemperli. Then, in June, the British pharma ponied up $1 billion to swallow<\/a> China\u2019s Siran Biotechnology, an RNA specialist with an investigational long-acting siRNA therapy called SA030 being positioned as a weight loss therapy.<\/p>\n

<\/p>\n

\"Business<\/p>\n

<\/a><\/p>\n

\n With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.\n <\/p>\n

May 7, 2026<\/p>\n

\u00a0\u00b7\u00a0<\/p>\n

2 min read<\/p>\n

\u00a0\u00b7\u00a0<\/p>\n

GSK has also inked several other deals this year, including the $2.2 billion takeover<\/a> of allergy player RAPT Therapeutics in January, which marked CEO Luke Miels\u2019 first major pickup since becoming<\/a> the company\u2019s top executive in September 2025. In June, GSK acquired Nuvalent Bio, developer of precision oncology assets, for $10.6 billion<\/a>\u2014a deal that ranks among 2026\u2019s largest so far<\/a>.<\/p>\n

<\/p>\n

\"Contemporary<\/p>\n

<\/a><\/p>\n

\n The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.\n <\/p>\n

July 1, 2026<\/p>\n

\u00a0\u00b7\u00a0<\/p>\n

1 min read<\/p>\n

\u00a0\u00b7\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"GSK continues to look eastward for novel assets, this time partnering with Hong Kong-based HUTCHMED to develop an…\n","protected":false},"author":2,"featured_media":116756,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[20785],"class_list":["post-116755","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-gsk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117207372070814153","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/116755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=116755"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/116755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/116756"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=116755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=116755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=116755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}